Pre-launch · We're opening Reserve Meds to a limited first cohort. Join the waitlist ›
Home / Drugs / Enhertu

Enhertu, trastuzumab deruxtecan

Named-patient access overview. Enhertu is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.

About Enhertu

Enhertu (trastuzumab deruxtecan) is manufactured by Daiichi/AZ and indicated for HER2 solid tumors. It is a HER2 ADC approved by the US FDA in 2019 and may be accessible to international patients through Named Patient Program or personal-import pathways.

How Reserve Meds coordinates Enhertu

  1. Patient or treating physician submits a named-patient request.
  2. Clinical team verifies appropriateness of Enhertu for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific NPP / personal-import documentation is prepared.
  5. Enhertu is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Access by country

Reserve Meds publishes a detailed country deep-dive for Enhertu in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Enhertu in BangladeshFull deep-dive on regulatory pathway, costs, timing Enhertu in EgyptFull deep-dive on regulatory pathway, costs, timing Enhertu in IndiaFull deep-dive on regulatory pathway, costs, timing Enhertu in NepalFull deep-dive on regulatory pathway, costs, timing Enhertu in OmanFull deep-dive on regulatory pathway, costs, timing Enhertu in PakistanFull deep-dive on regulatory pathway, costs, timing Enhertu in Saudi ArabiaFull deep-dive on regulatory pathway, costs, timing Enhertu in Sri LankaFull deep-dive on regulatory pathway, costs, timing Enhertu in TurkeyFull deep-dive on regulatory pathway, costs, timing Enhertu in the UAEFull deep-dive on regulatory pathway, costs, timing

Start a request for Enhertu

Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.

Join the Enhertu waitlist

About Enhertu

Oncology (Breast/Gastric)
Manufacturer: Daiichi/AZ
Modality: HER2 ADC
Generic: trastuzumab deruxtecan

Why Reserve Meds

DSCSA-compliant US sourcing. Physician-led. On-pathway in every destination. Patient-first intake with a named concierge.

Related

Access pathways
Country guidance
Articles & guides